Sonrotoclax
Product Specifications
UNSPSC Description
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1].
Target Antigen
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sonrotoclax.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
Molecular Weight
890.10
References & Citations
[1]Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-148026/Sonrotoclax-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-148026/Sonrotoclax-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2383086-06-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6315267-01 0.1 mL
LASP1, ID (LASP1, MLN50, LIM and SH3 domain protein 1, Metastatic lymph node gene 50 protein) (MaxLight 490)
Ask
View Details MBS6315267-02 5x 0.1 mL
LASP1, ID (LASP1, MLN50, LIM and SH3 domain protein 1, Metastatic lymph node gene 50 protein) (MaxLight 490)
Ask
View Details